Seroprevalence of anti-SARS-CoV-2 IgG antibodies pre- and post-COVID-19 vaccination in staff members of Bandar Abbas Children's Hospital

被引:0
作者
Tariverdi, Marjan [1 ]
Mohammadi, Hossein [2 ]
Hassanzadeh, Farideh [3 ]
Tamaddondar, Mohammad [4 ]
机构
[1] Hormozgan Univ Med Sci, Fac Med, Dept Pediat, Bandar Abbas, Iran
[2] Hormozgan Univ Med Sci, Student Res Comm, Bandar Abbas, Iran
[3] Hormozgan Univ Med Sci, Childrens Hosp, Clin Res Dev Ctr, Dept Pediat, Bandar Abbas, Iran
[4] Hormozgan Univ Med Sci, Shahid Mohammadi Hosp, Dept Nephrol & Internal Med, Bandar Abbas, Iran
关键词
COVID-19; Healthcare workers; Seroprevalence; Vaccination; SARS-COV; COVID-19; EFFICACY;
D O I
10.1186/s12879-023-08863-z
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BackgroundHealthcare workers (HCWs) have a higher risk of contracting coronavirus disease 2019 (COVID-19) compared to the general population due to their frontline role and direct contact with the infected patients. Accordingly, they were among the first groups to receive vaccination against COVID-19. A higher risk of COVID-19 infection may also exist among hospital staff members other than HCWs. In this study, we assessed the seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG pre- and post-COVID-19 vaccination in hospital staff members.MethodsThis cross-sectional study included 228 staff members of Bandar Abbas Children's Hospital, Bandar Abbas, Iran, who were recruited from 2020 to 2021. Staff members were vaccinated with vector and inactivated vaccines. Anti-SARS-CoV-2 spike protein IgG was measured in their blood samples pre- and post-COVID-19 vaccination.ResultsOf the 228 hospital staff members evaluated in this study (mean age: 37.59 +/- 8.70 years), 204 (89.5%) were female and 210 (92.1%) were HCWs. Only one staff member was not vaccinated, the rest received one dose (99.6%), and 224 (98.7%) two doses. Vector vaccines were administered to 71.4% of staff members and 72.9% of HCWs. Anti-SARS-CoV-2 IgG antibody was positive in 8.8% of staff members before vaccination, 9.3% after the first dose, and 50% after the second dose. The corresponding percentages were 9.5%, 9.5%, and 48.8% in HCWs. Being a HCW was not associated with the seroprevalence of anti-SARS-CoV-2 IgG after the second dose; however, multivariable binary logistic regression analysis revealed that the interval between two vaccine doses (adjusted odds ratio [aOR] = 0.595, 95% confidence interval [CI] 0.434; 0.816, P = 0.001) and age (aOR = 1.062, 95% CI 1.021; 1.105, P = 0.003) were associated with seroprevalence.ConclusionsAfter receiving a second dose of vector or inactive virus vaccines, our hospital's staff members and HCWs had a seroprevalence of anti-SARS-CoV-2 IgG antibodies of around 50%. Seroprevalence increased with increasing age and shorter intervals between doses.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Role of vaccination and anti-SARS-CoV-2 antibodies in the clinical outcome of hospitalized COVID-19 patients
    Bernal, Enrique
    Garcia-Villalba, Eva
    Pons, Eduardo
    Vicente, Maria Rosario
    Tomas, Cristina
    Minguela, Alfredo
    MEDICINA CLINICA, 2023, 160 (11): : 476 - 483
  • [22] Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?
    Lippi, Giuseppe
    Henry, Brandon Michael
    Plebani, Mario
    DIAGNOSTICS, 2021, 11 (06)
  • [23] Assessing the Pre-Vaccination Anti-SARS-CoV-2 IgG Seroprevalence among Residents and Staff in Nursing Home in Niigata, Japan, November 2020
    Wagatsuma, Keita
    Yoshioka, Sayaka
    Yamazaki, Satoru
    Sato, Ryosuke
    Phyu, Wint Wint
    Chon, Irina
    Takahashi, Yoshiki
    Watanabe, Hisami
    Saito, Reiko
    VIRUSES-BASEL, 2022, 14 (11):
  • [24] Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset
    Figueiredo-Campos, Patricia
    Blankenhaus, Birte
    Mota, Catarina
    Gomes, Andreia
    Serrano, Marta
    Ariotti, Silvia
    Costa, Catarina
    Nunes-Cabaco, Helena
    Mendes, Antonio M.
    Gaspar, Pedro
    Pereira-Santos, M. Conceicao
    Rodrigues, Fabiana
    Condeco, Jorge
    Escoval, M. Antonia
    Santos, Matilde
    Ramirez, Mario
    Melo-Cristino, Jose
    Simas, J. Pedro
    Vasconcelos, Eugenia
    Afonso, Angela
    Veldhoen, Marc
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2020, 50 (12) : 2025 - 2040
  • [25] Snapshot of Anti-SARS-CoV-2 IgG Antibodies in COVID-19 Recovered Patients in Guinea
    Grayo, Solene
    Sagno, Houlou
    Diassy, Oumar
    Zogbelemou, Jean-Baptiste
    Kondabo, Sia Jeanne
    Houndekon, Marilyn
    Dellagi, Koussay
    Vigan-Womas, Ines
    Rourou, Samia
    Hamouda, Wafa Ben
    Benabdessalem, Chaouki
    Ahmed, Melika Ben
    Tordo, Noel
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (10)
  • [26] Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines
    Alharbi, Naif Khalaf
    Al-Tawfiq, Jaffar A.
    Alwehaibe, Amal
    Alenazi, Mohamed W.
    Almasoud, Abdulrahman
    Algaisi, Abdullah
    Alhumaydhi, Fahad A.
    Hashem, Anwar M.
    Bosaeed, Mohammed
    Alsagaby, Suliman A.
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 4127 - 4136
  • [27] Prevalence of salivary anti-SARS-CoV-2 IgG antibodies in vaccinated children
    Badano, Maria Noel
    Duarte, Alejandra
    Salamone, Gabriela
    Sabbione, Florencia
    Pereson, Matias
    Chuit, Roberto
    Bare, Patricia
    IMMUNOLOGY, 2023, 169 (03) : 384 - 387
  • [28] Seroprevalence of anti-SARS-CoV-2 in patients with hepatitis B and C: a pre-vaccination study
    Silva, Lucas Lima da
    Lewis-Ximenez, Lia Laura
    Magalhaes, Monica de Avelar Figueiredo Mafra
    de Paula, Vanessa Salete
    Villar, Livia Melo
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2024, 28 (03)
  • [29] Seroprevalence of anti-SARS-CoV-2 IgG antibodies among children attending the pediatric hospital in Bamako, Mali (BamaCoV-Kids Study)
    Maiga, Almoustapha Issiaka
    Kodio, Amadou
    Ouedraogo, Salimata Alou
    Balde, Aliou
    Dembele, Penda
    Traore, Fatoumata Tata
    Dolo, Oumar
    Togo, Josue
    Coulibaly, Yacouba Aba
    Sylla, Mariam
    Murphy, Robert L.
    Marcelin, Anne-Genevieve
    Calvez, Vincent
    Diakite, Abdoul Aziz
    Todesco, Eve
    BMC INFECTIOUS DISEASES, 2025, 25 (01) : 429
  • [30] Role of Xenosialylation in Post-Infectious and Post-Vaccination Complications, Including Covid-19 and Anti-SARS-CoV-2 Vaccination
    Carnevali, Fiorella
    Mangiaterra, Sara
    Rossi, Giacomo
    JOURNAL OF INFLAMMATION RESEARCH, 2024, 17 : 8385 - 8394